Analyst Price Targets — MDWD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 12:09 pm | Jeff Jones | Oppenheimer | $30.00 | $13.58 | TheFly | MediWound price target lowered to $30 from $32 at Oppenheimer |
| May 28, 2026 9:18 pm | — | Industrial Alliance Securities | $22.00 | $14.56 | TheFly | MediWound price target lowered to $22 from $25 at Alliance Global |
| May 27, 2026 8:07 pm | Jay Olson | Oppenheimer | $32.00 | $14.33 | StreetInsider | MediWound Ltd (MDWD) PT Lowered to $32 at Oppenheimer |
| November 21, 2025 11:06 am | — | H.C. Wainwright | $36.00 | $16.86 | TheFly | MediWound price target raised to $36 from $31 at H.C. Wainwright |
| May 22, 2025 10:14 am | Swayampakula Ramakanth | H.C. Wainwright | $31.00 | $20.34 | TheFly | MediWound price target raised to $31 from $25 at H.C. Wainwright |
| February 28, 2025 1:57 pm | — | Craig-Hallum | $39.00 | $16.60 | TheFly | Craig-Hallum starts MediWound with Buy on EscharEx potential |
| October 11, 2024 6:38 am | Swayampakula Ramakanth | H.C. Wainwright | $28.00 | $16.92 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on MediWound Ltd (MDWD) |
| May 29, 2024 12:42 pm | Francois Brisebois | Oppenheimer | $36.00 | $16.01 | StreetInsider | Oppenheimer Reiterates Outperform Rating on MediWound Ltd (MDWD) |
| January 4, 2023 4:27 am | — | H.C. Wainwright | $23.00 | $13.29 | Benzinga | HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $23 |
| December 30, 2022 9:10 am | — | Cowen & Co. | $25.00 | $13.49 | Benzinga | Cowen & Co. Maintains Outperform on MediWound, Adjusts Price Target to $25 - 1-for-7 Reverse Stock Split |
Latest News for MDWD
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.
MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.23 per share a year ago.
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) --…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDWD.
U.S. House Trading
No House trades found for MDWD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.